General
- Lamivudine
is a potent nucleoside analog reverse transcriptase inhibitor.
- Lamivudine
is administered orally, and it is rapidly absorbed with a bio-availability
of over 80%. Some research suggests that lamivudine can cross the
blood-brain barrier.
Process
- Lamivudine
is an analogue of cytidine.
- It can
inhibit both types of HIV reverse transcriptase and also the reverse
transcriptase of hepatitis B.
- It needs to
be phosphorylated to its triphosphate form before it is active.
-
3TC-triphosphate also inhibits cellular DNA polymerase.
Report
- Lamivudine
is a nucleoside analogue, which was originally licensed for the treatment
of HIV.
- It is now
additionally licensed for the treatment of chronic hepatitis B with
evidence of viral replication.
- It is
marketed by GlaxoSmithKline with the brand names Zeffix, Heptovir, Epivir,
and Epivir-HBV.
Application
- Lamivudine
has been used for treatment of chronic hepatitis B at a lower dose than
for treatment of HIV.
- It improves
the sero conversion of e-antigen positive hepatitis B and also improves
histology staging of the liver.
Entrepreneur who want the
information on Product, Process,
Market, Msds, Patent, Consultants, Application Can email us to
informer@eth.net ,
primaryinfo@gmail.com
|
